Mangoceuticals (MGRX) Cash from Operations (2023 - 2026)

Mangoceuticals has disclosed Cash from Operations across 4 years of filings, most recently posting -$260506.0 for Q2 2026.

• In Q2 2026, Cash from Operations rose 79.27% year-over-year to -$260506.0; the TTM figure through Jun 2026 stood at -$3.9 million (up 33.22% YoY), while the FY2025 annual figure was -$5.9 million, down 20.28% from the prior year.
• Cash from Operations came in at -$260506.0 for Q2 2026 at Mangoceuticals, up from -$1.3 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of -$260506.0 in Q2 2026 to a low of -$2.3 million in Q1 2025.
• Average Cash from Operations over 4 years is -$1.4 million, with a median of -$1.3 million recorded in 2025.
• Year-over-year, Cash from Operations plunged 129.51% in 2025 and jumped 79.27% in 2026.
• Over 4 years, Cash from Operations stood at -$1.7 million in 2023, then surged by 33.47% to -$1.1 million in 2024, then increased by 4.59% to -$1.1 million in 2025, then soared by 75.83% to -$260506.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were -$260506.0 in Q2 2026, -$1.3 million in Q1 2026, and -$1.1 million in Q4 2025.